Broadly neutralizing antibodies suggest new prospects to counter highly antigenically diverse viruses
Identifieur interne : 000788 ( Ncbi/Merge ); précédent : 000787; suivant : 000789Broadly neutralizing antibodies suggest new prospects to counter highly antigenically diverse viruses
Auteurs : Dennis R. Burton [États-Unis] ; Pascal Poignard [États-Unis] ; Robyn L. Stanfield [États-Unis] ; Ian A. Wilson [États-Unis]Source :
- Science (New York, N.Y.) [ 0036-8075 ] ; 2012.
Abstract
Certain human pathogens avoid elimination by our immune system by rapidly mutating the surface antigen protein sites targeted by antibody responses and consequently they tend to be refractory to vaccine development. The behavior described is prominent for a subset of viruses-the highly antigenically diverse viruses-which include HIV, influenza and hepatitis C viruses. However, these viruses do harbor highly conserved exposed sites, usually associated with function, which can be targeted by broadly neutralizing antibodies. Until recently, not many such antibodies were known but advances in the field have enabled increasing numbers to be identified. Molecular characterization of the antibodies and, most importantly, of the sites of vulnerability that they recognize, gives hope for the discovery of new vaccines and drugs.
Url:
DOI: 10.1126/science.1225416
PubMed: 22798606
PubMed Central: 3600854
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000799
- to stream Pmc, to step Curation: 000799
- to stream Pmc, to step Checkpoint: 000748
Links to Exploration step
PMC:3600854Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Broadly neutralizing antibodies suggest new prospects to counter highly antigenically diverse viruses</title><author><name sortKey="Burton, Dennis R" sort="Burton, Dennis R" uniqKey="Burton D" first="Dennis R." last="Burton">Dennis R. Burton</name><affiliation wicri:level="2"><nlm:aff id="A1">Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="2"><nlm:aff id="A2">Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02129, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02129</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Poignard, Pascal" sort="Poignard, Pascal" uniqKey="Poignard P" first="Pascal" last="Poignard">Pascal Poignard</name><affiliation wicri:level="2"><nlm:aff id="A1">Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="2"><nlm:aff id="A4">International AIDS Vaccine Initiative (IAVI), New York, NY 10038, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>International AIDS Vaccine Initiative (IAVI), New York, NY 10038</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Stanfield, Robyn L" sort="Stanfield, Robyn L" uniqKey="Stanfield R" first="Robyn L." last="Stanfield">Robyn L. Stanfield</name><affiliation wicri:level="2"><nlm:aff id="A3">Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wilson, Ian A" sort="Wilson, Ian A" uniqKey="Wilson I" first="Ian A." last="Wilson">Ian A. Wilson</name><affiliation wicri:level="2"><nlm:aff id="A3">Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22798606</idno><idno type="pmc">3600854</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600854</idno><idno type="RBID">PMC:3600854</idno><idno type="doi">10.1126/science.1225416</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000799</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000799</idno><idno type="wicri:Area/Pmc/Curation">000799</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000799</idno><idno type="wicri:Area/Pmc/Checkpoint">000748</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000748</idno><idno type="wicri:Area/Ncbi/Merge">000788</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Broadly neutralizing antibodies suggest new prospects to counter highly antigenically diverse viruses</title><author><name sortKey="Burton, Dennis R" sort="Burton, Dennis R" uniqKey="Burton D" first="Dennis R." last="Burton">Dennis R. Burton</name><affiliation wicri:level="2"><nlm:aff id="A1">Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="2"><nlm:aff id="A2">Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02129, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02129</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Poignard, Pascal" sort="Poignard, Pascal" uniqKey="Poignard P" first="Pascal" last="Poignard">Pascal Poignard</name><affiliation wicri:level="2"><nlm:aff id="A1">Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation><affiliation wicri:level="2"><nlm:aff id="A4">International AIDS Vaccine Initiative (IAVI), New York, NY 10038, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>International AIDS Vaccine Initiative (IAVI), New York, NY 10038</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Stanfield, Robyn L" sort="Stanfield, Robyn L" uniqKey="Stanfield R" first="Robyn L." last="Stanfield">Robyn L. Stanfield</name><affiliation wicri:level="2"><nlm:aff id="A3">Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wilson, Ian A" sort="Wilson, Ian A" uniqKey="Wilson I" first="Ian A." last="Wilson">Ian A. Wilson</name><affiliation wicri:level="2"><nlm:aff id="A3">Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</nlm:aff><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Science (New York, N.Y.)</title><idno type="ISSN">0036-8075</idno><idno type="eISSN">1095-9203</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Certain human pathogens avoid elimination by our immune system by rapidly mutating the surface antigen protein sites targeted by antibody responses and consequently they tend to be refractory to vaccine development. The behavior described is prominent for a subset of viruses-the highly antigenically diverse viruses-which include HIV, influenza and hepatitis C viruses. However, these viruses do harbor highly conserved exposed sites, usually associated with function, which can be targeted by broadly neutralizing antibodies. Until recently, not many such antibodies were known but advances in the field have enabled increasing numbers to be identified. Molecular characterization of the antibodies and, most importantly, of the sites of vulnerability that they recognize, gives hope for the discovery of new vaccines and drugs.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">0404511</journal-id><journal-id journal-id-type="pubmed-jr-id">7473</journal-id><journal-id journal-id-type="nlm-ta">Science</journal-id><journal-id journal-id-type="iso-abbrev">Science</journal-id><journal-title-group><journal-title>Science (New York, N.Y.)</journal-title></journal-title-group><issn pub-type="ppub">0036-8075</issn><issn pub-type="epub">1095-9203</issn></journal-meta><article-meta><article-id pub-id-type="pmid">22798606</article-id><article-id pub-id-type="pmc">3600854</article-id><article-id pub-id-type="doi">10.1126/science.1225416</article-id><article-id pub-id-type="manuscript">NIHMS448730</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Broadly neutralizing antibodies suggest new prospects to counter highly antigenically diverse viruses</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Burton</surname><given-names>Dennis R.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Poignard</surname><given-names>Pascal</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Stanfield</surname><given-names>Robyn L.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>Ian A.</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Immunology and Microbial Science and International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</aff><aff id="A2"><label>2</label>Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02129, USA.</aff><aff id="A3"><label>3</label>Department of Molecular Biology, Skaggs Institute for Chemical Biology, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</aff><aff id="A4"><label>4</label>International AIDS Vaccine Initiative (IAVI), New York, NY 10038, USA.</aff><author-notes><corresp id="CR1"><label>*</label>Correspondence to: Dennis R. Burton, Ph.D. (<email>burton@scripps.edu</email>) or Ian A. Wilson, Ph.D. (<email>wilson@scripps.edu</email>)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>28</day><month>2</month><year>2013</year></pub-date><pub-date pub-type="ppub"><day>13</day><month>7</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>7</month><year>2013</year></pub-date><volume>337</volume><issue>6091</issue><fpage>183</fpage><lpage>186</lpage><abstract><p id="P1">Certain human pathogens avoid elimination by our immune system by rapidly mutating the surface antigen protein sites targeted by antibody responses and consequently they tend to be refractory to vaccine development. The behavior described is prominent for a subset of viruses-the highly antigenically diverse viruses-which include HIV, influenza and hepatitis C viruses. However, these viruses do harbor highly conserved exposed sites, usually associated with function, which can be targeted by broadly neutralizing antibodies. Until recently, not many such antibodies were known but advances in the field have enabled increasing numbers to be identified. Molecular characterization of the antibodies and, most importantly, of the sites of vulnerability that they recognize, gives hope for the discovery of new vaccines and drugs.</p></abstract><funding-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>R01 AI084817 || AI</award-id></award-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>P01 AI082362 || AI</award-id></award-group></funding-group></article-meta></front></pmc><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Massachusetts</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Burton, Dennis R" sort="Burton, Dennis R" uniqKey="Burton D" first="Dennis R." last="Burton">Dennis R. Burton</name></region><name sortKey="Burton, Dennis R" sort="Burton, Dennis R" uniqKey="Burton D" first="Dennis R." last="Burton">Dennis R. Burton</name><name sortKey="Poignard, Pascal" sort="Poignard, Pascal" uniqKey="Poignard P" first="Pascal" last="Poignard">Pascal Poignard</name><name sortKey="Poignard, Pascal" sort="Poignard, Pascal" uniqKey="Poignard P" first="Pascal" last="Poignard">Pascal Poignard</name><name sortKey="Stanfield, Robyn L" sort="Stanfield, Robyn L" uniqKey="Stanfield R" first="Robyn L." last="Stanfield">Robyn L. Stanfield</name><name sortKey="Wilson, Ian A" sort="Wilson, Ian A" uniqKey="Wilson I" first="Ian A." last="Wilson">Ian A. Wilson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000788 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000788 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:3600854
|texte= Broadly neutralizing antibodies suggest new prospects to counter highly antigenically diverse viruses
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22798606" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |